Apyx Medical Q2 Loss Widens Slightly Amidst Stable Per-Share Metrics
Ticker: APYX · Form: 10-Q · Filed: Aug 7, 2025 · CIK: 719135
| Field | Detail |
|---|---|
| Company | Apyx Medical Corp (APYX) |
| Form Type | 10-Q |
| Filed Date | Aug 7, 2025 |
| Risk Level | medium |
| Sentiment | bearish |
Sentiment: bearish
Topics: Medical Devices, Quarterly Earnings, Net Loss, SEC Filing, Advanced Energy, Financial Performance, R&D Expenses
Related Tickers: APYX
TL;DR
**Apyx Medical's Q2 loss widened, signaling continued financial headwinds despite stable per-share numbers; don't expect a quick turnaround.**
AI Summary
Apyx Medical Corp reported a net loss of $1.05 million for the second quarter of 2025, a slight increase from the $1.00 million net loss in the second quarter of 2024. For the six months ended June 30, 2025, the net loss was $4.12 million, compared to $3.99 million for the same period in 2024. The company's basic and diluted net loss per share remained consistent at $0.001 for both the three and six months ended June 30, 2025, and 2024, based on 37,793,886 common shares outstanding. The Advanced Energy segment incurs significant expenses including salaries, R&D, and professional services, while the OEM segment's expenses are primarily recorded as cost of sales. Corporate & Other expenses include legal, accounting, investor relations, and board compensation. The company's strategic outlook remains focused on managing these operational costs while pursuing growth in its medical device segments.
Why It Matters
Apyx Medical's consistent net loss, despite stable per-share figures, signals ongoing profitability challenges that investors should scrutinize. The company's ability to manage its significant R&D and professional service costs in the Advanced Energy segment will be crucial for future growth and competitive positioning against larger medical device manufacturers. For employees, continued losses could impact job security or future compensation, while customers might see slower product innovation if R&D is constrained. The broader market will watch if Apyx can carve out a sustainable niche in the competitive medical technology sector.
Risk Assessment
Risk Level: medium — The company reported a net loss of $1.05 million for Q2 2025 and $4.12 million for the first six months of 2025, indicating ongoing unprofitability. While the per-share loss remained stable at $0.001, the consistent losses suggest a medium risk level due to sustained operational challenges and the need for effective cost management, particularly in the Advanced Energy segment's R&D and professional services.
Analyst Insight
Investors should monitor Apyx Medical's future filings closely for signs of improved revenue generation or significant cost reductions, especially within its Advanced Energy segment. Consider holding off on new investments until there's clear evidence of a path to profitability, as current trends suggest continued financial pressure.
Financial Highlights
- net Income
- -$1.05M
- eps
- -$0.001
Key Numbers
- $1.05M — Q2 2025 Net Loss (Increased from $1.00M in Q2 2024, indicating widening losses.)
- $4.12M — YTD 2025 Net Loss (Increased from $3.99M in YTD 2024, showing sustained unprofitability.)
- $0.001 — Net Loss Per Share (Consistent for both Q2 and YTD 2025 and 2024, despite widening net losses.)
- 37,793,886 — Common Shares Outstanding (Basis for per-share calculations, indicating stable share count.)
Key Players & Entities
- Apyx Medical Corp (company) — filer of the 10-Q
- $1.05 million (dollar_amount) — net loss for Q2 2025
- $1.00 million (dollar_amount) — net loss for Q2 2024
- $4.12 million (dollar_amount) — net loss for six months ended June 30, 2025
- $3.99 million (dollar_amount) — net loss for six months ended June 30, 2024
- $0.001 (dollar_amount) — basic and diluted net loss per share for Q2 2025 and Q2 2024
- 37,793,886 (dollar_amount) — common shares outstanding
- Advanced Energy segment (company) — segment with significant R&D and professional service expenses
- OEM segment (company) — segment where expenses are primarily cost of sales
- Bloomberg (company) — publisher of this analysis
FAQ
What was Apyx Medical Corp's net loss for the second quarter of 2025?
Apyx Medical Corp reported a net loss of $1.05 million for the second quarter of 2025, which is an increase from the $1.00 million net loss reported in the second quarter of 2024.
How did Apyx Medical's year-to-date net loss compare between 2024 and 2025?
For the six months ended June 30, 2025, Apyx Medical's net loss was $4.12 million, compared to $3.99 million for the same period in 2024, indicating a slight increase in losses.
What was the basic and diluted net loss per share for Apyx Medical in Q2 2025?
The basic and diluted net loss per share for Apyx Medical was $0.001 for the second quarter of 2025, remaining consistent with the $0.001 reported in Q2 2024.
How many common shares were outstanding for Apyx Medical Corp as of June 30, 2025?
As of June 30, 2025, Apyx Medical Corp had 37,793,886 common shares outstanding, which is the basis for the per-share calculations.
What are the primary expenses for Apyx Medical's Advanced Energy segment?
The Advanced Energy segment's primary expenses include salaries and related costs, research and development, professional services (including marketing and physician consulting), and other selling, general, and administrative expenses such as travel and entertainment.
Where are the expenses for Apyx Medical's OEM segment primarily recorded?
For the OEM segment, substantially all related expenses are recorded as cost of sales, meaning no significant segment-specific operating expenses are incurred separately.
What types of expenses fall under Apyx Medical's Corporate & Other category?
Corporate & Other expenses include salaries and related costs, professional services (legal, accounting, audit, investor relations, IT consulting), board of directors’ stock compensation expense, and general and administrative expenses like insurance and building lease costs.
What is the risk level associated with Apyx Medical's Q2 2025 filing?
The risk level is assessed as medium due to the company's consistent net losses, including $1.05 million in Q2 2025 and $4.12 million year-to-date, indicating ongoing profitability challenges.
What should investors consider regarding Apyx Medical's financial performance?
Investors should note the widening net losses and the stable but negative per-share results. It is advisable to monitor for clear signs of improved revenue or significant cost management before making new investment decisions.
What is the significance of Apyx Medical's consistent $0.001 net loss per share?
The consistent $0.001 net loss per share, despite increasing total net losses, indicates that the number of outstanding shares has remained stable, diluting the impact of the larger absolute loss across the same equity base.
Risk Factors
- Sustained Net Losses [high — financial]: Apyx Medical Corp reported a net loss of $1.05 million for Q2 2025, an increase from $1.00 million in Q2 2024. The year-to-date net loss for 2025 was $4.12 million, up from $3.99 million in the same period of 2024. This trend indicates persistent unprofitability and a widening loss trajectory.
- High Operating Expenses [medium — operational]: The Advanced Energy segment incurs significant expenses, including salaries, R&D, and professional services. Corporate & Other expenses also contribute substantially, covering legal, accounting, investor relations, and board compensation. Managing these costs is critical for future profitability.
- Dependence on Medical Device Segments [medium — market]: The company's strategic outlook is focused on growth within its medical device segments. Any slowdown or challenges in these specific markets could materially impact the company's financial performance and ability to achieve profitability.
Industry Context
Apyx Medical Corp operates in the surgical and medical instruments and apparatus industry. This sector is characterized by innovation, regulatory scrutiny, and competition from both established players and emerging companies. Trends include the development of minimally invasive surgical tools and advancements in energy-based technologies.
Regulatory Implications
As a medical device company, Apyx Medical Corp is subject to stringent regulations from bodies like the FDA. Compliance with quality standards, manufacturing practices, and product approvals is critical. Any regulatory setbacks or changes in the regulatory landscape could significantly impact product development, market access, and financial performance.
What Investors Should Do
- Monitor expense management closely.
- Evaluate growth drivers in medical device segments.
- Assess cash burn rate.
Glossary
- Advanced Energy segment
- A business segment of Apyx Medical Corp that likely focuses on energy-related technologies or applications within the medical field, incurring significant operational and R&D expenses. (This segment is a major driver of the company's expenses, impacting overall profitability.)
- OEM segment
- Original Equipment Manufacturer segment, where the company likely supplies components or products to other businesses, with related expenses primarily recorded as cost of sales. (This segment's cost structure is simpler, with most expenses tied directly to revenue generation.)
- Corporate & Other
- A category encompassing central corporate functions and expenses not directly attributable to specific operating segments, including legal, accounting, investor relations, and board compensation. (These overhead costs are a significant factor in the company's overall expense structure.)
- Net loss per share
- The portion of a company's profit or loss allocated to each outstanding share of common stock. Calculated by dividing net income (or loss) by the weighted-average number of outstanding shares. (Indicates the profitability on a per-share basis, which remained stable at $0.001 despite widening net losses.)
Year-Over-Year Comparison
The second quarter of 2025 saw a slight increase in net loss to $1.05 million compared to $1.00 million in the prior year's quarter. Similarly, the year-to-date net loss widened to $4.12 million from $3.99 million. Despite these widening losses, the net loss per share remained stable at $0.001, supported by a consistent share count of 37,793,886. No new significant risk factors were explicitly detailed in the provided excerpt, but the existing trends of increasing losses and high operating expenses remain key concerns.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 7, 2025 regarding Apyx Medical Corp (APYX).